In this issue:
sNFL chain for prognostication of disease activity in MS
mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in MS
Impact of the COVID-19 pandemic on DMT prescribing for MS
Immune response to the third COVID-19 vaccine is related to lymphocyte count in MS patients treated with fingolimod
Rebound activity after fingolimod cessation
Reporting of race and ethnicity in phase III trials of MS DMTs
Short-chain fatty acids during pregnancy in MS
Cladribine after alemtuzumab in the treatment of MS
Efficacy and safety of temelimab in MS
Eculizumab monotherapy for NMOSD
Please login below to download this issue (PDF)